Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,022 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Wong SJ, et al. Among authors: winter k. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1367-75. doi: 10.1016/j.ijrobp.2011.05.027. Epub 2011 Jul 19. Int J Radiat Oncol Biol Phys. 2012. PMID: 21775070 Free PMC article. Clinical Trial.
Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.
Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV. Lawton CA, et al. Among authors: winter k. Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):931-9. doi: 10.1016/s0360-3016(97)00288-5. Int J Radiat Oncol Biol Phys. 1997. PMID: 9276357 Clinical Trial.
Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group.
Grigsby PW, Winter K, Wasserman TH, Marcial V, Rotman M, Cooper J, Keys H, Asbell SO, Phillips TL. Grigsby PW, et al. Among authors: winter k. Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):513-7. doi: 10.1016/s0360-3016(99)00054-1. Int J Radiat Oncol Biol Phys. 1999. PMID: 10348279 Clinical Trial.
Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.
Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV. Lawton CA, et al. Among authors: winter k. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937-46. doi: 10.1016/s0360-3016(00)01516-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11240234 Clinical Trial.
Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy.
Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Horwitz EM, et al. Among authors: winter k. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):947-56. doi: 10.1016/s0360-3016(00)01443-7. Int J Radiat Oncol Biol Phys. 2001. PMID: 11240235 Clinical Trial.
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Pilepich MV, et al. Among authors: winter k. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52. doi: 10.1016/s0360-3016(01)01579-6. Int J Radiat Oncol Biol Phys. 2001. PMID: 11483335 Clinical Trial.
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gynecology Cancer Working Group.
Greven KM, Levenback C, Chao CK, Delaney T, Del Priore G, Eifel P, Erickson BA, Followill D, Gaffney D, Garcia M, Gerszten K, Grigsby P, Henderson R, Hricak H, Hsu J, Jhingrin A, Kaye A, Kudelka A, Lukka H, Mutch D, Nag S, Rotman M, Shefter T, Smith W, Stehman F, Souhami L, Wenzel L, Winter KA, Wolfson A; Radiation Therapy Oncology Group. Greven KM, et al. Among authors: winter ka. Int J Radiat Oncol Biol Phys. 2001;51(3 Suppl 2):58-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11641017 No abstract available.
RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, Michalski J, Purdy J. Valicenti RK, et al. Among authors: winter k. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):614-20. doi: 10.1016/s0360-3016(03)00640-0. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529764 Clinical Trial.
RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. Hagan MP, et al. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665-72. doi: 10.1016/s0360-3016(03)00718-1. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529770 Clinical Trial.
Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T; Radiation Therapy Oncology Group. Greven K, et al. Among authors: winter k. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73. doi: 10.1016/j.ijrobp.2003.10.019. Int J Radiat Oncol Biol Phys. 2004. PMID: 15093913 Clinical Trial.
1,022 results